These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1846478)

  • 1. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 2. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 3. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
    Chiu A; Landsberg D; Cameron EC; Manson AD; Shackleton C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1039-40. PubMed ID: 1899146
    [No Abstract]   [Full Text] [Related]  

  • 6. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
    Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
    [No Abstract]   [Full Text] [Related]  

  • 7. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of the HLA-DRw6 antigen in liver transplantation.
    Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
    [No Abstract]   [Full Text] [Related]  

  • 9. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 10. MALG vs OKT3 following renal transplantation: a randomized prospective trial.
    Frey DJ; Matas AJ; Gillingham KJ; Canafax D; Payne WD; Dunn DL; Sutherland DE; Najarian JS
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1048-9. PubMed ID: 1899149
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of a randomized monoclonal or polyclonal program of therapy on cytomegalovirus infection in kidney transplantation.
    Raffaele P; Pouteil-Noble C; Lefrancois N; Bosshard S; Betuel H; Aymard M; Dubernard JM; Touraine JL
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1361-2. PubMed ID: 1846465
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful pancreas-renal transplantation without anti-T-cell antibody induction.
    Shapiro ME; Abrams JM; Brown RS; Steinman TI; Strom TB
    Transplant Proc; 1995 Dec; 27(6):3087-8. PubMed ID: 8539857
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antirejection treatment in kidney transplantation--is there a proved rationale for the general use of monoclonal antibodies?
    Reis HJ; Hopt UT; Greger B; Schareck WD; Bockhorn H
    Transplant Proc; 1987 Oct; 19(5):3565-9. PubMed ID: 2823424
    [No Abstract]   [Full Text] [Related]  

  • 16. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion effect still present with quadruple immunosuppression in recipients of renal transplants.
    Yang HC; Weaver AS; Gifford RR
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1247-8. PubMed ID: 1899159
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
    Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period.
    Hesse UJ; Wienand P; Baldamus C; Arns W
    Transplant Proc; 1990 Oct; 22(5):2273-4. PubMed ID: 2120814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.